EDN plus usual treatment for advanced liver cancer after first therapy fails
Part of Cancer, Digestive system clinical trials.
This study tests whether adding a special procedure (called EDN) to the usual treatments (TACE or HAIC) can help people with advanced liver cancer that has spread into a main blood vessel of the liver, after a first treatment stopped working. It may help make the treatment work better or for longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- Your liver cancer must have spread into a main blood vessel (portal vein) but not beyond a certain point.
- You must have tried at least one standard treatment for your cancer, and it didn't work or your cancer grew.
- Your doctor must be planning to treat your tumor with a procedure called TACE or HAIC (delivering medicine directly to the tumor through a tube).
- You must be generally able to care for yourself and be up and about (with or without some help).
- Your liver and kidney function must be within safe limits for this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver. It tests whether combining a TACE procedure with immunotherapy and anti-angiogenesis drugs can improve outcomes. You must not have had prior systemic therapy and must have received TACE in a specific time window around starting these drugs.
This trial tests adding a second liver-directed treatment (hepatic artery infusion) to the usual combination of targeted therapy (lenvatinib) and chemoembolization (DEB-TACE) for people with large liver cancer that has spread into the portal vein, to see if the triple therapy works better.
This study tests a combined treatment for liver cancer that cannot be removed with surgery. It combines a targeted therapy pill (donafenib) with a procedure that delivers chemotherapy directly to the tumor (E-TACE). The goal is to see if this combination helps control the cancer and is safe for patients.
This trial tests a new combination of two immunotherapy drugs plus a targeted therapy and a procedure called TACE (which blocks the blood supply to the tumor) for people with advanced liver cancer. It aims to see if this combination can shrink tumors and help patients live longer.
This trial tests an experimental oral drug (ETN101) for adults with advanced liver cancer (hepatocellular carcinoma) that has gotten worse after standard treatments or can't be treated with standard therapy. It aims to see if the drug is safe and effective.
This trial tests a combination of a focused radiation beam (SBRT) plus a pill that helps stop tumor blood vessel growth (lenvatinib) and a procedure that blocks blood flow to the tumor (TACE) for people with advanced liver cancer that has not yet spread outside the liver. The goal is to see if this triple therapy can improve outcomes without prior treatment.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.